On finding widest empty curved corridors

Open archive-ElsevierAn α-siphon of width w is the locus of points in the plane that are at the same distance w from a 1-corner polygonal chain C such that α is the interior angle of C. Given a set P of n points in the plane and a fixed angle α, we want to compute the widest empty α-siphon that splits P into two non-empty sets.We present an efficient O(n log3 n)-time algorithm for computing the widest oriented α-siphon through P such that the orientation of a half-line of C is known.We also propose an O(n3 log2 n)-time algorithm for the widest arbitrarily-oriented version and an (nlog n)-time algorithm for the widest arbitrarily-oriented α-siphon anchored at a given point

The siphon problem

An α-siphon is the locus of points in the plane that are at the same distance ǫ from a polygonal chain consisting of two half-lines emanating from a common point such that α is the interior angle of the half-lines. Given a set S of n points in the plane and a fixed angle α, we want to compute an α-siphon of largest width ǫ such that no points of S lies in its interior. We present an efficient O(n2)-time algorithm for computing an orthogonal siphon. The approach can be handled to solve the problem of the oriented α-siphon for which the orientation of a half-line is known. We also propose an O(n3 log n)-time algorithm for the arbitrarily oriented version.Ministerio de Ciencia y TecnologiaFondo Europeo de Desarrollo RegionalGeneralitat de Cataluny

Covering point sets with two disjoint disks or squares

Open archive-ElsevierWe study the following problem: Given a set of red points and a set of blue points on the plane, find two unit disks CR and CB with disjoint interiors such that the number of red points covered by CR plus the number of blue points covered by CB is maximized. We give an algorithm to solve this problem in O(n8/3 log2 n) time, where n denotes the total number of points. We also show that the analogous problem of finding two axis-aligned unit squares SR and SB instead of unit disks can be solved in O(nlog n) time, which is optimal. If we do not restrict ourselves to axis-aligned squares, but require that both squares have a common orientation, we give a solution using O(n3 log n) time

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio